clinical trial · NCT04238793
Single Ascending Doses Study of KLS-2031 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy
Kolon Life Science·phase2·completed·n = 18
Neuropathic Pain From Lumbosacral RadiculopathyKLS-2031Placebo
brief summary
Escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031
started
Apr 16, 2020
primary completion
Oct 18, 2023
completion
Oct 18, 2023
last updated
Jul 29, 2024
detailed description
This is a first-in-human (FIH), multicenter, double-blind, placebo-controlled, parallel-group, escalating single-dose design study to determine the safety, tolerability, and analgesic activity of KLS-2031 administered by transforaminal epidural injection to subjects aged 18 to 75 years with neuropathic pain due to LSR.
official title
A Phase 1/2a, First-in-Human, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Therapeutic Activity of Single Ascending Doses of KLS-2031 Administered by Transforaminal Epidural Injection in Patients With Neuropathic Pain From Lumbosacral Radiculopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol